Yescarta
Israeli Oncologists Show Point-of-Care CAR T Cells Have Comparable Efficacy to Yescarta, Kymriah
Premium
Lymphoma patients better tolerated the CAR T-cell therapy manufactured on-site at the Sheba Medical Center than they did the commercially available options.
Gilead Sciences to Lay Off 72 Employees, Shutter Seattle Office
The cuts, which will go into effect mid-January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.
Gilead has high hopes that anito-cel, a multiple myeloma cell therapy it is developing with Arcellx, can bolster its cell therapy franchise.
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Revenues for the firm's antibody-drug conjugate Trodelvy grew 39 percent year over year in Q1 2024 due to increased demand.